INQOVI Drug Patent Profile

Which patents cover Inqovi, and when can generic versions of Inqovi launch?

Inqovi is a drug marketed by Taiho Oncology and is included in one NDA. There are six patents protecting this drug.

This drug has ninety-six patent family members in forty-two countries.

The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this compound. Additional details are available on the cedazuridine; decitabine profile page.

DrugPatentWatch^® Generic Entry Outlook for Inqovi

Inqovi was eligible for patent challenges on July 7, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 24, 2041. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INQOVI

International Patents:	96
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	15
Clinical Trials:	28
Drug Prices:	Drug price information for INQOVI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INQOVI
What excipients (inactive ingredients) are in INQOVI?	INQOVI excipients list
DailyMed Link:	INQOVI at DailyMed

See drug prices for INQOVI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INQOVI

Constraining patent/regulatory exclusivity:

11,963,971

NDA:

212576

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INQOVI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Break Through Cancer	EARLY_PHASE1
Astex Pharmaceuticals, Inc.	EARLY_PHASE1
Lachelle D. Weeks, MD, PhD	EARLY_PHASE1

See all INQOVI clinical trials

Pharmacology for INQOVI

Drug Class	Nucleoside Metabolic Inhibitor
Mechanism of Action	Nucleic Acid Synthesis Inhibitors

US Patents and Regulatory Information for INQOVI

INQOVI is protected by eleven US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 11,963,971.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	12,239,653
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	8,618,075
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	8,268,800			Y
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	11,963,971		Y
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	9,567,363			Y

International Patents for INQOVI

When does loss-of-exclusivity occur for INQOVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Mexico

Philippines

Poland

Portugal

Saudi Arabia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INQOVI around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2021071890
Spain	2384011
Spain	2992301
Japan	5859588
Finland	C20230040
South Africa	201002178	2'-FLUORO-2'-DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS

Supplementary Protection Certificates for INQOVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2207786	PA2023539	Lithuania		PRODUCT NAME: KOMPOZICIJA, APIMANTI: CEDAZURIDINA ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; IR DECITABINAS; REGISTRATION NO/DATE: EU/1/23/1756 20230915
2207786	2390033-5	Sweden		PRODUCT NAME: A COMBINATION OF: CEDAZURIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AND DECITABINE; REG. NO/DATE: EU/1/23/1756 20230918
2207786	43/2023	Austria		PRODUCT NAME: CEDAZURIDIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1756 (MITTEILUNG) 20230918
2207786	44/2023	Austria		PRODUCT NAME: EINE ZUSAMMENSETZUNG UMFASSEND DIE KOMBINATION AUS CEDAZURIDIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND DECITABIN; REGISTRATION NO/DATE: EU/1/23/1756 (MITTEILUNG) 20230918
2207786	PA2023538,C2207786	Lithuania		PRODUCT NAME: CEDAZURIDINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1756 20230915
2207786	C20230040	Finland

INQOVI (decitabine/cedazuridine) Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

INQOVI is an oral fixed-dose combination of decitabine plus cedazuridine approved for myelodysplastic syndromes (MDS), with commercial performance driven by (1) penetration in lower-risk and higher-risk segments where hypomethylating agents are standard, (2) formulary access and payer step edits versus injectables, (3) competitive pressure from other oral or parenteral hypomethylating strategies, and (4) the durability of uptake after launch. The financial trajectory is primarily determined by net sales momentum, rebilling and channel behavior for an oral oncology product, and the pace of geographic and guideline adoption within MDS subtypes.

What is the commercial basis for INQOVI’s market demand?

Indication and positioning

INQOVI (decitabine/cedazuridine) targets MDS, a disease category with sustained disease-management demand because patients typically require repeated cycles rather than one-time curative therapy.

The product’s market position depends on replacing part of the decitabine injectable use with an oral regimen that preserves clinical intent while reducing administration burden.

Core buyer value propositions that affect uptake

• Administration shift: oral dosing reduces clinic infusion capacity needs versus injectable decitabine, supporting payer and provider adoption.
• Workflow fit: oral administration improves throughput and reduces treatment-day logistics that limit injectable hypomethylating agents in community settings.
• Continuity of therapy: lower friction supports sustained cycle adherence, which matters to payers focused on real-world persistence.

Competitive landscape affecting switching behavior

INQOVI competes in the “hypomethylating agent” space, where switching is constrained by evidence hierarchy, patient history, and reimbursement rules. Uptake is usually strongest where:

• oral convenience is aligned with payer policies,
• dosing schedules and patient monitoring are manageable in outpatient workflows, and
• clinicians already use hypomethylating therapy as a baseline standard for the relevant MDS risk strata.

How do market dynamics shape INQOVI’s pricing and payer access?

Payer mechanics for an oral oncology therapy

Oral oncology drugs often face a payer pathway that includes:

• Formulary placement decisions (preferred versus non-preferred),
• Prior authorization (to confirm diagnosis and line of therapy),
• Step edits versus injectables when payers attempt to preserve cost parity, and
• Quantity and cycle limits aligned to dosing.

These mechanics affect early uptake and can create non-linear sales growth, including step-function changes after formulary wins.

Channel behavior and rebilling dynamics

Because INQOVI is oral, the sales curve is influenced by:

• Pharmacy benefit manager (PBM) contracting and rebilling timing,
• Copay assistance participation affecting net price, and
• Patient-start conversion after prior authorization approval.

For oral products, “channel inventory” and “patient starts” can diverge in the short term, so reported revenue trends often reflect both demand and distribution timing.

Guideline adoption and sequencing effects

Market dynamics in MDS are driven by:

• clinician preference for specific hypomethylating regimens,
• patient fitness for outpatient treatment,
• sequencing after prior therapy (including prior hypomethylating exposure),
• and evolving guideline language around oral options.

The implication for financial trajectory is that sales do not only depend on new patient incidence, but also on patient pool churn between MDS treatment lines.

What drives INQOVI’s financial trajectory over time?

Revenue drivers

INQOVI’s financial path is shaped by a set of recurring levers:

1. Net sales growth from new patient starts

   • dependent on prescriber adoption and payer approvals.

2. Persistence and dose intensity

   • tied to cycle adherence and discontinuation rates.

3. Net pricing

   • influenced by rebate dynamics, contract penetration, and patient assistance.

4. Geographic expansion

   • affected by local reimbursement status and labeling scope.

5. Competitor response

   • includes promotional intensity and formulary pressure from competing agents.

Typical non-linearities in oral oncology sales

Sales curves for oral oncolytics frequently show:

• launch-to-early adoption ramp,
• payer-driven slowdowns when prior authorization becomes bottleneck,
• and step increases following formulary wins.

What investors and business buyers track

To forecast INQOVI’s next-year performance and beyond, the most decision-relevant indicators are:

• formulary share and tier position,
• PBM contract updates and rebate rate shifts,
• prescription-to-patient-start conversion,
• and persistence measures (patients remaining on therapy after defined cycles).

How has INQOVI performed commercially versus benchmarks in the MDS market?

A complete benchmark comparison requires consistent time-series net sales data and competitor net revenue data across the same reporting periods. Without a verified dataset in this response, a quantitative side-by-side chart cannot be produced.

What can be stated at a business-logic level is that INQOVI’s trajectory is linked to the size of the addressable MDS treatment pool and the rate of switching from parenteral decitabine to an oral regimen. That switching is slower when payers require step edits and when clinicians perceive injectable regimens as default for patients with prior treatment exposure.

What are the key market risks that can change INQOVI’s growth path?

1) Formulary and net price pressure

Oral convenience does not immunize against margin compression if:

• PBMs renegotiate preferred pricing,
• payers intensify prior authorization requirements, or
• competing oral options force price convergence.

2) Evidence and label interpretation risk

If clinical practice shifts toward other regimens based on emerging data, prescribers may narrow INQOVI use for specific MDS subgroups.

3) Competitive substitution

In MDS, competitive substitution can accelerate when:

• a rival regimen is placed on preferred tiers,
• access barriers for INQOVI remain high, or
• clinical pathways define another option as preferred after earlier-line therapy.

4) Channel dynamics that mask demand

In oral oncology, reported sales can be distorted by distributor or pharmacy inventory behavior. That can create short-term volatility even when underlying patient starts remain stable.

How does the product’s structure influence long-term commercial outcomes?

INQOVI is a fixed-dose combination of decitabine and cedazuridine designed to maintain decitabine exposure after oral dosing. That mechanistic positioning affects commercialization in two ways:

• Clinicians can treat it as an oral substitute rather than a distinct therapy class, which lowers switching friction.
• Payers can evaluate it within known hypomethylating agent value frameworks.

This structure supports adoption when payer policies accept oral hypomethylating agents as clinically equivalent for coverage purposes.

Key Takeaways

• INQOVI’s market demand is driven by sustained MDS treatment cycles and outpatient-friendly administration that reduces clinic resource burden.
• Its financial trajectory depends on payer formulary status, prior authorization throughput, and oral-channel rebilling behavior that can create non-linear sales ramps.
• Growth is reinforced by persistence and patient-start conversion, while risks concentrate in net pricing pressure, competitive formulary placement, and shifting MDS sequencing practices.
• The most decision-relevant monitoring points are formulary share, PBM contract terms, net price and rebate rate movement, and persistence metrics by cycle number.

FAQs

1) Who buys INQOVI?

Major customers are US commercial payers via PBM networks and institutional providers. Coverage decisions flow through formulary and prior authorization rules that determine patient-start conversion.

2) What most impacts INQOVI net sales in the near term?

Net sales are most sensitive to formulary tier placement, prior authorization approval velocity, and oral-channel buying behavior that affects timing of inventory and rebill.

3) Why does oral administration matter for MDS drugs?

Oral administration reduces infusion center demand and can lower logistics costs for providers and patients, supporting adoption when payer rules allow oral hypomethylating coverage.

4) What competitive threats are most relevant?

Competitive threats are typically other hypomethylating options and any oral or parenteral regimen that gains preferred formulary placement or becomes preferred in sequencing guidance.

5) What metrics best forecast longer-term performance?

Forecasting depends on persistence (on-therapy cycles), patient-start conversion rates, and net pricing trends driven by rebate and contracting dynamics.

---

References

[1] FDA. “INQOVI (decitabine and cedazuridine) prescribing information.” U.S. Food and Drug Administration.